Second agreement signed with Novartis to develop novel degraders for immune-mediated diseases, providing upfront payment of $120 million plus option maintenance payments, and eligibility for option ...
Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback